The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task

Psychopharmacology
Samuel A BarnesBéla Kiss

Abstract

Attentional processing deficits are a core feature of schizophrenia, likely contributing to the persistent functional and occupational disability observed in patients with schizophrenia. The pathophysiology of schizophrenia is hypothesized to involve dysregulation of NMDA receptor-mediated glutamate transmission, contributing to disruptions in normal dopamine transmission. Preclinical investigations often use NMDA receptor antagonists, such as phencyclidine (PCP), to induce cognitive disruptions relevant to schizophrenia. We sought to test the ability of partial dopamine D2/D3 agonists, cariprazine and aripiprazole, to attenuate PCP-induced deficits in attentional performance. The objective of this study is to determine whether systemic administration of cariprazine or aripiprazole attenuated 5-choice serial reaction time task (5-CSRTT) deficits induced by repeated exposure to PCP. We utilized a repeated PCP-treatment regimen (2 mg/kg, subcutaneous [s.c.], once daily for 5 days) in rats to induce deficits in the 5-CSRTT. Rats were pre-treated with cariprazine (0.03, 0.1, or 0.3 mg/kg, oral [p.o.]) or aripiprazole (1, 3, or 10 mg/kg, p.o.) to determine whether they prevented PCP-induced deficits in the 5-CSRTT performance. PCP t...Continue Reading

References

Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Apr 29, 1998·Journal of Clinical Psychopharmacology·T Sharma, D Mockler
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D Jentsch, R H Roth
Mar 30, 1999·Journal of Molecular Neuroscience : MN·V D NairR K Mishra
Aug 22, 2001·European Journal of Pharmacology·A W SchmidtS H Zorn
Dec 12, 2001·Schizophrenia Research·Dawn I VelliganAlexander L Miller
Jul 20, 2002·Progress in Neurobiology·André Nieoullon
May 1, 2004·Psychopharmacology·Patricia S Goldman-RakicGraham V Williams
Nov 9, 2004·Schizophrenia Research·Robert S KernBi-Hong Deng
May 16, 2006·Trends in Neurosciences·John H R Maunsell, Stefan Treue
Jul 18, 2006·Current Pharmaceutical Design·Wim J RiedelPieter J Unema
Aug 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·E Pomarol-ClotetP C Fletcher
Jun 27, 2007·Journal of Psychopharmacology·P R CorlettP C Fletcher
Jul 10, 2007·Schizophrenia Bulletin·John A Gray, Bryan L Roth
Mar 4, 2008·British Journal of Pharmacology·J A PrattB J Morris
Sep 6, 2008·Progress in Brain Research·Vasileios Boulougouris, Eleftheria Tsaltas
Sep 28, 2010·Annual Review of Pharmacology and Toxicology·Hisham M Ibrahim, Carol A Tamminga
Jul 1, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Megan St PetersMartin Sarter
Jul 7, 2011·Proceedings of the National Academy of Sciences of the United States of America·Yan-Chun LiWen-Jun Gao
Oct 3, 2012·Handbook of Experimental Pharmacology·Gerhard Gross, Karla Drescher
Oct 17, 2012·Molecular Psychiatry·C S WeickertT W Weickert
Dec 18, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Christina A Wilson, James I Koenig
May 9, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Malte FejaMichael Koch
May 23, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Agnieszka Nikiforuk, Piotr Popik

❮ Previous
Next ❯

Citations

Sep 13, 2019·The Journal of Pharmacology and Experimental Therapeutics·Mei HuangHerbert Y Meltzer
Nov 14, 2019·British Journal of Pharmacology·Maria A MeierZoltan Gerevich
Jul 11, 2018·Journal of Psychopharmacology·Chris BarkusTrevor Sharp
Apr 24, 2019·CNS Spectrums·Francesca CalabreseMarco A Riva
Oct 24, 2019·Expert Opinion on Pharmacotherapy·Gayatri SarafLakshmi N Yatham
Jan 29, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Domenico De BerardisMassimo Di Giannantonio

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
MedPC
Statsoft Statistica

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.